$1.23 Billion is the total value of Perceptive Advisors's 196 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 326.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $53,802,000 | +46.9% | 2,334,168 | +5.7% | 3.47% | +36.8% |
| VSAR | Buy | VERSARTIS INC | $49,351,000 | +57.4% | 4,028,685 | +42.1% | 3.19% | +46.6% |
| NXTM | Buy | NXSTAGE MEDICAL INC | $41,726,000 | +39.2% | 1,669,703 | +20.8% | 2.69% | +29.6% |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $22,191,000 | +105.2% | 683,448 | +30.8% | 1.43% | +90.9% |
| CLCD | New | COLUCID PHARMACEUTICALS INC | $21,060,000 | – | 552,030 | +100.0% | 1.36% | – |
| QTNT | Buy | QUOTIENT LTD | $20,893,000 | +19.9% | 2,671,794 | +18.8% | 1.35% | +11.7% |
| DBVT | Buy | DBV TECHNOLOGIES SA-SPON ADRdepository receipt | $20,464,000 | +14.8% | 563,268 | +3.0% | 1.32% | +6.9% |
| RGNX | Buy | REGENXBIO INC | $17,964,000 | +104.3% | 1,282,286 | +16.7% | 1.16% | +90.2% |
| RDUS | New | RADIUS HEALTH INC | $16,957,000 | – | 313,502 | +100.0% | 1.10% | – |
| FLML | New | FLAMEL TECHNOLOGIES -SP ADRdepository receipt | $16,910,000 | – | 1,363,711 | +100.0% | 1.09% | – |
| KDMN | New | KADMON INC | $16,218,000 | – | 2,209,657 | +100.0% | 1.05% | – |
| DXCM | Buy | DEXCOM INC | $15,678,000 | +57.9% | 178,849 | +42.9% | 1.01% | +47.1% |
| AERI | New | AERIE PHARMACEUTICALS INC | $15,352,000 | – | 406,771 | +100.0% | 0.99% | – |
| ARDX | New | ARDELYX INC | $13,680,000 | – | 1,057,257 | +100.0% | 0.88% | – |
| ALDR | New | ALDER BIOPHARMACEUTICALS INC | $12,822,000 | – | 391,280 | +100.0% | 0.83% | – |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $12,717,000 | +151.9% | 1,373,284 | +72.7% | 0.82% | +134.6% |
| New | CYTOMX THERAPEUTICS, INCpreferred stock | $11,634,000 | – | 742,021 | +100.0% | 0.75% | – | |
| ZYNE | Buy | ZYNERBA PHARMACEUTICALS INC | $11,339,000 | +94.9% | 868,897 | +2.3% | 0.73% | +81.6% |
| ACRS | New | ACLARIS THERAPEUTICS INC | $11,012,000 | – | 430,000 | +100.0% | 0.71% | – |
| VBIV | New | VBI VACCINES INC | $10,490,000 | – | 3,058,433 | +100.0% | 0.68% | – |
| MYOK | Buy | MYOKARDIA INC | $10,374,000 | +66.4% | 634,894 | +26.2% | 0.67% | +55.1% |
| FWP | Buy | FORWARD PHARMA A/S-ADRdepository receipt | $8,494,000 | +50.1% | 404,472 | +29.9% | 0.55% | +39.8% |
| ABMD | New | ABIOMED INC | $8,138,000 | – | 63,290 | +100.0% | 0.52% | – |
| AVXS | Buy | AVEXIS INC | $7,830,000 | +13400.0% | 190,000 | +12441.3% | 0.50% | +12525.0% |
| ACHN | New | ACHILLION PHARMACEUTICALS | $7,527,000 | – | 929,290 | +100.0% | 0.49% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP SHS PUT 12 12/16/2016put | $7,180,000 | – | 16,000 | +100.0% | 0.46% | – |
| AGRX | Buy | AGILE THERAPEUTICS INC | $7,120,000 | +81.9% | 1,020,011 | +98.3% | 0.46% | +69.7% |
| AGEN | New | AGENUS INC | $6,462,000 | – | 900,000 | +100.0% | 0.42% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS INC | $6,228,000 | – | 847,458 | +100.0% | 0.40% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $6,183,000 | – | 171,500 | +100.0% | 0.40% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $6,179,000 | +142.0% | 762,800 | +76.2% | 0.40% | +125.4% |
| HSGX | New | HISTOGENCIS CORP | $5,706,000 | – | 1,777,777 | +100.0% | 0.37% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $5,606,000 | – | 777,669 | +100.0% | 0.36% | – |
| PTI | Buy | PROTEOSTASIS THERAPEUTICS INC | $5,372,000 | +77.1% | 344,550 | +37.8% | 0.35% | +65.2% |
| ADMA | New | ADMA BIOLOGICS INC | $5,327,000 | – | 734,793 | +100.0% | 0.34% | – |
| AMRN | New | AMARIN CORP PLC-ADRdepository receipt | $5,175,000 | – | 1,622,280 | +100.0% | 0.33% | – |
| CEMP | Buy | CEMPRA INC | $4,247,000 | +51.5% | 175,503 | +3.2% | 0.27% | +41.2% |
| BGNE | New | BEIGENE LTDdepository receipt | $4,069,000 | – | 132,057 | +100.0% | 0.26% | – |
| MYL | Buy | MYLAN NV | $3,610,000 | +1571.3% | 94,711 | +1794.2% | 0.23% | +1453.3% |
| OPHT | New | OPHTHOTECH CORP CALL 80 12/16/2016call | $2,740,000 | – | 600,000 | +100.0% | 0.18% | – |
| APVO | New | APTEVO THERAPEUTICS INC | $2,530,000 | – | 988,133 | +100.0% | 0.16% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $2,075,000 | – | 65,240 | +100.0% | 0.13% | – |
| ARNI | New | ARNO THERAPEUTICS INC | $1,963,000 | – | 4,177,577 | +100.0% | 0.13% | – |
| ABT | New | ABBOTT LABORATORIES | $1,946,000 | – | 46,019 | +100.0% | 0.13% | – |
| EIGR | Buy | EIGER BIOPHARMACEUTICALS INC | $1,739,000 | -16.4% | 129,920 | +23.8% | 0.11% | -22.2% |
| BIO | New | BIO RAD LABORATORIES CLASS A | $1,638,000 | – | 10,000 | +100.0% | 0.11% | – |
| VCRA | New | VOCERA COMMUNICATIONS INC | $1,593,000 | – | 94,236 | +100.0% | 0.10% | – |
| ALQA | New | ALLIQUA BIOMEDICAL INC | $1,537,000 | – | 1,921,951 | +100.0% | 0.10% | – |
| BCLI | New | BRAINSTORM CELL THERAPEUTICS | $964,000 | – | 400,000 | +100.0% | 0.06% | – |
| ATRS | New | ANTARES PHARMA INC | $912,000 | – | 0 | +100.0% | 0.06% | – |
| ONSIZ | Buy | ONCOBIOLOGICS INC*w exp 2/18/2017 | $787,000 | +289.6% | 656,382 | +41.9% | 0.05% | +264.3% |
| BIIB | New | BIOGEN INC | $601,000 | – | 1,921 | +100.0% | 0.04% | – |
| HRC | New | HILL ROM HOLDINGS INC | $593,000 | – | 9,563 | +100.0% | 0.04% | – |
| IMDZ | New | IMMUNE DESIGN CORP | $589,000 | – | 77,725 | +100.0% | 0.04% | – |
| HWAY | New | HEALTHWAYS INC | $572,000 | – | 21,608 | +100.0% | 0.04% | – |
| INCR | New | INC RESEARCH HOLDINGS INC CLASS A | $563,000 | – | 12,636 | +100.0% | 0.04% | – |
| HUM | New | HUMANA INC CALL 190 04/21/2017call | $526,000 | – | 400 | +100.0% | 0.03% | – |
| INCY | New | INCYTE CORP | $530,000 | – | 5,619 | +100.0% | 0.03% | – |
| ICLR | New | ICON INC | $532,000 | – | 6,873 | +100.0% | 0.03% | – |
| A | New | AGILENT TECHNOLOGIES INC | $496,000 | – | 10,540 | +100.0% | 0.03% | – |
| SGYPQ | New | SYNERGY PHARMACEUTICALS INC | $491,000 | – | 89,127 | +100.0% | 0.03% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $492,000 | – | 7,344 | +100.0% | 0.03% | – |
| AMAG | New | AMAG PHARMACEUTICALS INC | $479,000 | – | 19,524 | +100.0% | 0.03% | – |
| LNTH | New | LANTHEUS HOLDINGS INC | $445,000 | – | 53,763 | +100.0% | 0.03% | – |
| AMSG | New | AMSURG CORP | $444,000 | – | 6,618 | +100.0% | 0.03% | – |
| AFAM | New | ALMOST FAMILY INC | $439,000 | – | 11,942 | +100.0% | 0.03% | – |
| AMN | New | AMN HEALTHCARE INC | $428,000 | – | 13,445 | +100.0% | 0.03% | – |
| ANTM | New | ANTHEM INC | $426,000 | – | 3,400 | +100.0% | 0.03% | – |
| Q | New | QUINTILES IMS HOLDINGS INC | $414,000 | – | 5,103 | +100.0% | 0.03% | – |
| ONSIW | Buy | ONCOBIOLOGICS INC*w exp 2/18/2017 | $313,000 | +47.6% | 656,382 | +41.9% | 0.02% | +33.3% |
| MNKKQ | New | MALLINCKRODT PLC | $314,000 | – | 4,500 | +100.0% | 0.02% | – |
| ACHI | New | ACCRETIVE HEALTH INC | $305,000 | – | 125,000 | +100.0% | 0.02% | – |
| TDOC | New | TELADOC INC | $275,000 | – | 15,000 | +100.0% | 0.02% | – |
| BVX | New | BOVIE MEDICAL CORP | $253,000 | – | 48,544 | +100.0% | 0.02% | – |
| LLY | New | ELI LILLY & CO CALL 90 01/20/2017call | $250,000 | – | 1,000 | +100.0% | 0.02% | – |
| PMD | New | PSYCHEMEDICS CORP | $250,000 | – | 12,626 | +100.0% | 0.02% | – |
| ZGNX | New | ZOGENIX INC | $212,000 | – | 18,541 | +100.0% | 0.01% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $210,000 | – | 10,518 | +100.0% | 0.01% | – |
| GKOS | Buy | GLAUKOS CORP | $200,000 | +2122.2% | 5,300 | +1666.7% | 0.01% | +1200.0% |
| AMRI | New | ALBANY MOLECULAR RESEARCH | $170,000 | – | 10,300 | +100.0% | 0.01% | – |
| MTD | New | METTLER TOLEDO INTERNATIONAL | $174,000 | – | 415 | +100.0% | 0.01% | – |
| NUVA | New | NUVASIVE INC | $173,000 | – | 2,589 | +100.0% | 0.01% | – |
| ARAY | New | ACCURAY INC | $174,000 | – | 27,300 | +100.0% | 0.01% | – |
| LHCG | New | LHC GROUP INC | $175,000 | – | 4,745 | +100.0% | 0.01% | – |
| MDSO | New | MEDIDATA SOLUTIONS INC | $160,000 | – | 2,865 | +100.0% | 0.01% | – |
| BOLD | New | AUDENTES THERAPEUTICS INC | $134,000 | – | 7,500 | +100.0% | 0.01% | – |
| IVC | New | INVACARE CORP | $147,000 | – | 13,200 | +100.0% | 0.01% | – |
| ISRG | New | INTUITIVE SURGICAL INC | $145,000 | – | 200 | +100.0% | 0.01% | – |
| ATRC | New | ATRICURE INC | $126,000 | – | 7,949 | +100.0% | 0.01% | – |
| HNGR | New | HANGER INC | $128,000 | – | 15,038 | +100.0% | 0.01% | – |
| ACETQ | New | ACETO CORP | $115,000 | – | 6,054 | +100.0% | 0.01% | – |
| CYNO | New | CYNOSURE INC CLASS A | $92,000 | – | 1,800 | +100.0% | 0.01% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $23,000 | – | 250 | +100.0% | 0.00% | – |
| AVGR | New | AVINGER INC | $5,000 | – | 1,062 | +100.0% | 0.00% | – |
| SGMO | New | SANGAMO BIOSCIENCES INC | $1,000 | – | 272 | +100.0% | 0.00% | – |
| CRY | New | CRYOLIFE INC | $2,000 | – | 123 | +100.0% | 0.00% | – |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $3,000 | -100.0% | 544,770 | +81.6% | 0.00% | -100.0% |
| MD | New | MEDNAX INC | $2,000 | – | 29 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
| SC 13D | 2024-03-20 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.